Fluticasone Propionate
| Evidence Level: L5 | Predicted Indications: 57 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Fluticasone Propionate |
| DrugBank ID | DB00588 |
| Brand Names (EU) | Fluticasone propionate, Seffalair Spiromax |
| Evidence Level | L5 |
| Predicted Indications | 57 |
| Top Prediction Score | 99.65% |
Approved Indication (EMA)
Seffalair Spiromax is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting ?? agonists.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | atopic eczema | 99.65% | DL |
| 2 | dermatitis, atopic | 99.26% | DL |
| 3 | 2-hydroxyethyl methacrylate sensitization | 98.56% | DL |
| 4 | occupational dermatitis | 97.34% | DL |
| 5 | allergic asthma | 97.17% | DL |
| 6 | intrinsic asthma | 96.89% | DL |
| 7 | seborrheic dermatitis | 96.71% | DL |
| 8 | contact dermatitis | 96.67% | DL |
| 9 | vulvar inverted follicular keratosis | 96.37% | DL |
| 10 | seborrheic keratosis | 96.31% | DL |
| 11 | alopecia mucinosa | 96.11% | DL |
| 12 | telogen effluvium | 95.96% | DL |
| 13 | lichen disease | 95.95% | DL |
| 14 | alopecia areata | 95.94% | DL |
| 15 | Quinquaud’s folliculitis decalvans | 95.44% | DL |
| 16 | atopic dermatitis | 95.32% | DL |
| 17 | polyp of vocal cord | 95.00% | DL |
| 18 | hereditary hypotrichosis with recurrent skin vesicles | 94.96% | DL |
| 19 | polyp of middle ear | 94.94% | DL |
| 20 | epulis | 94.82% | DL |
Showing top 20 of 57 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.